Stocks › SBFM

Sunshine Biopharma Inc.

SBFM·Nasdaq·United States United States·USD
$2.23
-0.12 (-5.11%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
SBFM
Sunshine Biopharma Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
SBFMS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of SBFM by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Roger WilliamsRoger WilliamsHouse · R · TX SBFMSunshine Biopharma Inc. · Stock Purchase
$1,001 - $15,000
Jun 12, 2024 Jun 30, 2022 Filing ↗

Whale Activity

Position changes in SBFM reported for 2026-09-30 by 16 institutional filers
Increased: 3New: 5Held: 4Closed: 2No prior filing: 2
  • Increased3
  • New5
  • Held4
  • Decreased0
  • Closed2
  • No prior filing2

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by SBFM insiders, by quarter · Form 4

No open-market insider buys or sells in the last two years.

Recent Insider Transactions

55 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
NATAN DAVIDDirector Grant / award +58.3K $0.00 $0 Aug 7, 2026 Form 4 ↗
NATAN DAVIDDirector Grant / award +100.0K $0.00 $0 Apr 14, 2026 Form 4 ↗
Slilaty Steve N.Chief Executive Officer · Director · 10% owner Purchase +100.0K $0.10 $10K Mar 4, 2024 Form 4 ↗
Slilaty Steve N.Chief Executive Officer · Director · 10% owner Purchase +20.0K n/c — Feb 8, 2024 Form 4 ↗
Sebaaly CamilleCFO/Secretary Purchase +30.0K $0.76 $23K Nov 30, 2022 Form 4 ↗
Sebaaly CamilleCFO/Secretary Purchase +25.0K $1.22 $31K Jun 3, 2022 Form 4 ↗
Slilaty Steve N.Chief Executive Officer · Director Disposition to issuer −990.0K $0.10 $99K Feb 18, 2022 Form 4 ↗
MERZOUKI ABDERRAZZAKChief Operating Officer · Director Grant / award +20.0M $0.00 $0 Jan 6, 2021 Form 4 ↗
Slilaty Steve N.Chief Executive Officer · Director Grant / award +20.0M $0.00 $0 Jan 6, 2021 Form 4 ↗
Sebaaly CamilleCFO/Secretary · Director Grant / award +20.0M $0.00 $0 Jan 6, 2021 Form 4 ↗
Slilaty Steve N.Chief Executive Officer · Director Grant / award +500.0K $0.10 $50K Jun 17, 2020 Form 4 ↗
Sebaaly CamilleCFO/Secretary · Director Grant / award −323.7K $0.00 $0 Dec 31, 2019 Form 4 ↗
Slilaty Steve N.Chief Executive Officer · Director Other +323.7K $0.00 $0 Dec 31, 2019 Form 4 ↗
Sebaaly CamilleCFO/Secretary · Director Grant / award +1.3M $0.00 $0 Dec 19, 2019 Form 4 ↗
MERZOUKI ABDERRAZZAKChief Operating Officer · Director Grant / award +1.3M $0.00 $0 Dec 19, 2019 Form 4 ↗
Slilaty Steve N.Chief Executive Officer · Director Grant / award +1.3M $0.00 $0 Dec 19, 2019 Form 4 ↗
Sebaaly CamilleCFO/Secretary · Director Grant / award +1.1M $0.00 $0 Oct 20, 2019 Form 4 ↗
MERZOUKI ABDERRAZZAKChief Operating Officer · Director Grant / award +1.1M $0.00 $0 Oct 20, 2019 Form 4 ↗
Slilaty Steve N.Chief Executive Officer · Director Grant / award +1.1M $0.00 $0 Oct 20, 2019 Form 4 ↗
Sebaaly CamilleCFO/Secretary · Director Grant / award +550.0K $0.00 $0 Sep 11, 2019 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding SBFM · SEC Form N-PORT

No mutual fund or ETF has reported SBFM in an N-PORT filing in the last seven months.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Intracoastal Capital LLCSCHEDULE 13G/A · passive (13G) · 430.3K shares10.0%
    Nov 10, 2026 · ↗
  • Daniel B. AsherSCHEDULE 13G/A · passive (13G) · 430.3K shares10.0%
    Nov 10, 2026 · ↗
  • Mitchell P. KopinSCHEDULE 13G/A · passive (13G) · 430.3K shares10.0%
    Nov 10, 2026 · ↗
  • BJI Financial GroupSCHEDULE 13G · passive (13G) · 909.9K shares6.0%
    Oct 14, 2026 · ↗
  • Heights Capital Management, Inc.SCHEDULE 13G · passive (13G) · 1.6M shares9.9%
    Oct 13, 2026 · ↗
  • CVI Investments, Inc.SCHEDULE 13G · passive (13G) · 1.6M shares9.9%
    Oct 13, 2026 · ↗
  • Alta Partners LLCSCHEDULE 13G/A · passive (13G) · 200.0K shares4.9%
    Oct 5, 2026 · ↗
  • L1 Capital Global Opportunities Master Fund, Ltd.SCHEDULE 13G/A · passive (13G) · 111.5K shares5.0%
    Aug 14, 2026 · ↗
  • Intracoastal Capital LLCSCHEDULE 13G/A · passive (13G) · 235.7K shares10.0%
    Aug 13, 2026 · ↗
  • Daniel B. AsherSCHEDULE 13G/A · passive (13G) · 235.7K shares10.0%
    Aug 13, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming Sunshine Biopharma Inc. as client

No lobbying filings found naming Sunshine Biopharma Inc. as the client.

Government Contracts

Federal awards to Sunshine Biopharma Inc. · USAspending

No federal contract awards found for Sunshine Biopharma Inc..

U.S. Patents

Recent USPTO applications naming Sunshine Biopharma Inc.

No USPTO patent applications found for Sunshine Biopharma Inc..

Annual Financials

From SBFM's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$36.3M$34.9M$24.1M$4.3M$228K
Operating income-$6.2M-$5.8M-$4.8M-$27.0M-$2.4M
Net income-$6.0M-$5.1M-$4.5M-$26.7M-$12.4M
Diluted EPSn/a-$7.32-$351.36-$1.76-$4.76
Operating cash flow-$5.3M-$12.5M-$8.8M-$5.2M-$1.8M
Cash and equivalentsn/an/an/a$21.8M$2.0M
Total assets$30.1M$30.6M$27.3M$29.2M$2.2M
Total liabilities$7.0M$7.1M$6.1M$7.6M$2.0M
Shareholders' equity$23.0M$23.5M$21.2M$21.6M$212K

As Sunshine Biopharma Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Apr 3, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-20Reverse splitOct 26, 2026
  • 1-for-10Reverse splitJun 1, 2026
  • 1-for-20Reverse splitAug 8, 2024
  • 1-for-100Reverse splitApr 17, 2024
  • 1-for-20Reverse splitFeb 1, 2019

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 5.07Shareholder voteOct 14, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsOct 9, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteSep 16, 2026
    EDGAR ↗
  • 8-K · Items 8.01Other eventsSep 11, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeAug 28, 2026
    EDGAR ↗
  • 8-K · Items 8.01Other eventsAug 3, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 9.01Material agreementJul 20, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteMay 29, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsMay 19, 2026
    EDGAR ↗

About Sunshine Biopharma Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersFORT LAUDERDALE, FL
IncorporatedCO
Former namesSunshine Biopharma, Inc, Mountain West Business Solutions, Inc, mountain west business solutions,inc